KMS Medisurgi

Why is KMS Medisurgi Ltd falling/rising?

As of 01-Sep, KMS Medisurgi Ltd's stock price is at Rs. 132.80, marking a new 52-week and all-time high. The stock has shown strong performance, outperforming its sector and indicating positive momentum with increased investor participation.

As of 01-Sep, KMS Medisurgi Ltd's stock price is rising, currently at Rs. 132.80, with no change in percentage terms (0.00%). The stock has reached a new 52-week and all-time high of Rs. 132.80 today, indicating strong performance. It opened with a gain of 4.98% and touched an intraday high of Rs. 132.80, reflecting positive momentum. Additionally, the stock has outperformed its sector by 8.7%, which suggests that it is performing better than its peers in the Medical Equipment/Supplies/Accessories sector, despite that sector experiencing a decline of -3.72%. <BR><BR>Moreover, KMS Medisurgi Ltd is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is typically a bullish indicator. There has also been a noted increase in investor participation, with delivery volume remaining stable compared to the 5-day average. These factors collectively contribute to the stock's rising price.

Who are in the management team of KMS Medisurgi?

The management team of KMS Medisurgi includes Rekha Devang Kanakia (Chairman & Managing Director), Kamlesh Chunilal Rajani, Hardik Rajnikant Bhatt, Pratik Pravin Tarpara (all Independent Directors), Siddharth Kanakia, Rohan Devang Kanakia (Directors), and Sunny Gupta (Company Secretary & Compliance Officer).

The management team of KMS Medisurgi includes the following individuals:<BR><BR>1. Rekha Devang Kanakia - Chairman & Managing Director<BR>2. Kamlesh Chunilal Rajani - Independent Director<BR>3. Hardik Rajnikant Bhatt - Independent Director<BR>4. Siddharth Kanakia - Director<BR>5. Pratik Pravin Tarpara - Independent Director<BR>6. Rohan Devang Kanakia - Director<BR>7. Sunny Gupta - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about KMS Medisurgi or its operations, feel free to ask!

What does KMS Medisurgi do?

KMS Medisurgi Ltd is a micro-cap healthcare services company that manufactures and coats substrates with adhesive. It was incorporated in 1999 and became public in 2016, with a current market cap of INR 42 Cr.

Overview: <BR>KMS Medisurgi Ltd is a micro-cap company in the healthcare services industry that manufactures and undertakes job work of coating various substrates with adhesive.<BR><BR>History: <BR>KMS Medisurgi Limited was incorporated as "KMS Medisurgi Private Limited" in 1999 and converted into a Public Limited Company on June 15, 2016. Revenue and profit data are not available for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 42 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 100.00 <BR>Industry P/E: 24 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.04 <BR>Return on Equity: 5.29% <BR>Price to Book: 5.02<BR><BR>Contact Details: <BR>Address: 297/301 May Building Grou. Flr, Marine (East) Princess Street Mumbai Maharashtra : 400002 <BR>Phone: 91-22-66107700/66107722 <BR>Email: kms.medisurgi@gmail.com <BR>Website: http://www.kmsgroup.in

Who are the peers of the KMS Medisurgi?

KMS Medisurgi's peers include Royal Sense, Shree Pacetronix, Amkay Products, N G Industries, Centenial Surgic, Bandaram Pharma, Deccan Healthcar, and Sunrest Lifescie. Management risk varies from excellent at some peers to below average at others, with growth and capital structure also differing significantly among them.

Peers: The peers of KMS Medisurgi are Royal Sense, Shree Pacetronix, Amkay Products, N G Industries, Centenial Surgic, Bandaram Pharma, Deccan Healthcar, and Sunrest Lifescie.<BR><BR>Quality Snapshot: Excellent management risk is observed at Royal Sense, Shree Pacetronix, Amkay Products, N G Industries, and Sunrest Lifescie, while Average management risk is found at KMS Medisurgi. Below Average management risk is noted at Centenial Surgic, Bandaram Pharma, and Deccan Healthcar. Growth is Excellent at Royal Sense and Bandaram Pharma, Good at Shree Pacetronix, Deccan Healthcar, and Sunrest Lifescie, while KMS Medisurgi, Amkay Products, N G Industries, and Centenial Surgic show Below Average growth. Capital Structure is Good at Royal Sense, Shree Pacetronix, Amkay Products, N G Industries, and Deccan Healthcar, Average at Centenial Surgic, and Below Average at Bandaram Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Amkay Products with N/A, while the lowest is Royal Sense at -62.36%, and KMS Medisurgi's own 1-year return is also N/A. Additionally, the six-month return is negative for Royal Sense, Shree Pacetronix, Bandaram Pharma, and Deccan Healthcar.

Which are the latest news on KMS Medisurgi?

How big is KMS Medisurgi?

As of 13th August, KMS Medisurgi Ltd has a market capitalization of 42.00 Cr, classified as a Micro Cap, with no valid financial data available for the latest four quarters. The latest balance sheet shows Shareholder's Funds of 8.09 Cr and Total Assets of 10.22 Cr as of March 2025.

As of 13th August, <BR><BR>Market Cap: KMS Medisurgi Ltd has a market capitalization of 42.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 8.09 Cr and Total Assets valued at 10.22 Cr.

When is the next results date for KMS Medisurgi Ltd?

The next results date for KMS Medisurgi Ltd is 30 May 2026.

The next results date for KMS Medisurgi Ltd is scheduled for 30 May 2026.

Is KMS Medisurgi overvalued or undervalued?

As of September 16, 2025, KMS Medisurgi is considered very expensive and overvalued with a PE ratio of 41.75, an EV to EBIT ratio of 41.87, and a Price to Book Value of 5.45, underperforming the Sensex and raising concerns about its growth prospects.

As of 16 September 2025, the valuation grade for KMS Medisurgi has moved from risky to very expensive. The company is currently considered overvalued, with a PE ratio of 41.75, an EV to EBIT ratio of 41.87, and a Price to Book Value of 5.45. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, KMS Medisurgi's PE ratio is lower than Poly Medicure's 56.1 but higher than Blue Jet Health's 34.66, indicating a mixed competitive positioning. The PEG ratio stands at 0.00, which raises concerns about growth prospects relative to its valuation. Notably, while KMS Medisurgi has delivered a 1.2% return year-to-date, it has underperformed the Sensex, which has returned 5.43% in the same period, further reinforcing the notion of overvaluation.

Who are the top shareholders of the KMS Medisurgi?

The top shareholders of KMS Medisurgi are Moni Diamonds Limited with 19.21% and Yagnesh Manaharlal Joshi as the highest public shareholder at 5.82%. Individual investors hold a total of 21.7%, with no mutual fund or foreign institutional investor holdings and no pledged promoter shares.

The top shareholders of KMS Medisurgi include Moni Diamonds Limited, which holds the highest stake at 19.21%. Additionally, Yagnesh Manaharlal Joshi is the highest public shareholder with a holding of 5.82%. Overall, individual investors collectively hold 21.7% of the company's shares. The company does not have any mutual fund or foreign institutional investor (FII) holdings, and there are no pledged promoter holdings.

What is the technical trend for KMS Medisurgi?

As of April 15, 2024, KMS Medisurgi's technical trend is neutral, with the price stagnant at 125.00 and no significant movement in the 52-week high or low.

As of 15 April 2024, the technical trend for KMS Medisurgi has changed from mildly bullish to does not qualify. The current price is stagnant at 125.00, matching the previous close, with no movement in the 52-week high or low. Given the lack of significant price action and the absence of technical summary data, there is insufficient information to determine a clear bullish or bearish stance. The overall technical outlook is neutral.

How has been the historical performance of the KMS Medisurgi?

KMS Medisurgi has shown stable financial performance from March 2019 to March 2024, with increased total reserves and shareholder's funds, reduced long-term debt, and improved book value per share, despite reporting no profit before tax during the period. Total assets and liabilities remained consistent, indicating growth in equity while managing debt levels effectively.

Answer:<BR>The historical performance of KMS Medisurgi shows a consistent trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>KMS Medisurgi has maintained a stable share capital of Rs 3.30 crore from March 2019 to March 2024. Total reserves have increased from Rs 2.95 crore in March 2019 to Rs 4.36 crore in March 2024, indicating a positive trend in retained earnings. Shareholder's funds have also risen from Rs 6.25 crore in March 2019 to Rs 7.66 crore in March 2024. Long-term borrowings have decreased from Rs 1.13 crore in March 2019 to Rs 0.54 crore in March 2024, reflecting a reduction in debt levels. Total liabilities increased from Rs 10.54 crore in March 2019 to Rs 10.73 crore in March 2024, while total assets grew from Rs 10.54 crore to Rs 10.73 crore in the same period. The book value per share has improved from Rs 18.95 in March 2019 to Rs 23.22 in March 2024. However, the company reported no profit before tax from March 2020 to March 2023, with a notable cash flow from operating activities consistently at Rs 0.00 during these years. Overall, KMS Medisurgi has shown growth in its equity and asset base while managing to reduce its long-term debt.

Has KMS Medisurgi declared dividend?

No Dividend History Available